Literature DB >> 26693404

D5S351 and D5S1414 located at the spinal muscular atrophy critical region represent novel informative markers in the Iranian population.

Maryam Sedghi1, Sadeq Vallian1.   

Abstract

Spinal muscular atrophy (SMA) is a degenerative neuromuscular disease associated with progressive symmetric weakness and atrophy of the limb muscles. In view of the involvement of numerous point mutations and deletions associated with the disease, the application of polymorphic markers flanking the SMA critical region could be valuable in molecular diagnosis of the disease. In the present study, D5S351 and D5S1414 polymorphic markers located at the SMA critical region in the Iranian populations were characterized. Genotyping of the markers indicated the presence of six and nine different alleles for D5S351 and D5S1414, respectively. Haplotype frequency estimation in 25 trios families and 75 unrelated individuals indicated the presence of six informative haplotypes with frequency higher than 0.05 in the studied population. Furthermore, the D' coefficient and the χ(2) value for D5S351 and D5S1414 markers revealed the presence of linkage disequilibrium between the two markers in the Iranians. These data suggested that D5S351 and D5S1414 could be suggested as informative markers for linkage analysis and molecular diagnosis of SMA in the Iranian population.

Entities:  

Keywords:  Carrier detection; Iranian population; Polymorphic markers; Spinal muscular Atrophy

Year:  2015        PMID: 26693404      PMCID: PMC4660382          DOI: 10.1016/j.mgene.2015.10.006

Source DB:  PubMed          Journal:  Meta Gene        ISSN: 2214-5400


Introduction

Spinal muscular atrophy (SMA) is a severe neuromuscular disease characterized by degeneration of the alpha motor neurons of the spinal cord associated with progressive symmetric weakness and atrophy of the limb muscles (Dubowitz, 2009). Different phenotypes identified in this disease were usually classified into three groups according to the age of onset and severity of the clinical symptoms, i) acute Werdnig–Hoffmann (type I), ii) intermediate Werdnig–Hoffmann (type II), and iii) Kugelberg–Welander disease (type III) (Chen et al., 1999). Molecular investigations had indicated that all these three types of disease were linked to the SMA critical region on chromosome 5q13 (Brzustowicz et al., 1990, Melki et al., 1990a, Melki et al., 1990b). A large duplication in this region contains two centromeric and telomeric homologous copies of at least 4 genes including survival motor neuron (SMN), neuronal apoptosis inhibitory protein (NAIP), p44 gene, a subunit of transcription factor TFIIH and H4F5 (Lefebvre et al., 1995, Roy et al., 1995, Burglen et al., 1997, Scharf et al., 1998). Deletions of telomeric copy of SMN (SMNt) have been observed in approximately 95% of the SMA patients (Zeesman et al., 2002). However, deletions of other genes of SMA critical region have been found mainly in the severe forms of the disease (Velasco et al., 1996, McAndrew et al., 1997, Scharf et al., 1998, Tsai et al., 2001, Feldkötter et al., 2002). Moreover, several subtle mutations which cause rare cases of the SMA disease have been reported in different populations (He et al., 2013, Zapletalová et al., 2007, Wirth, 2000). The SMA disease seems to be among the most common genetic diseases worldwide with an estimation of 1 in 6000 to 1 in 10,000 live births and the carrier frequency from 1:40 to 1:60 (Ogino et al., 2002, Prior et al., 2010). The frequency of the disease has been reported to be relatively high in the Iranian population. A recent report indicated a very high incidence of the disease with carrier frequency of 1 in 20 in the Iranian population (Hasanzad et al., 2010). This indicated the high demand and the necessity of carrier detection and prenatal diagnosis of the SMA disease in the Iranian population. The SMA gene region contains several polymorphic genetic markers including restriction fragment length polymorphisms (RFLPs) and short tandem repeats (STRs) (Wirth et al., 1993, Wirth et al., 1994, Chen et al., 2007). Polymorphic markers usually show various frequency and heterozygosity in different populations. Among the STRs present in the SMA gene region, D5S351 and D5S1414, which flank the critical region, could be used in molecular diagnosis of the SMA disease. However, no investigation has been performed on heterozygosity and allele frequency of these markers in the Iranian population. In the present study, we evaluated the polymorphism level and haplotype frequency of these two polymorphic markers in the Iranian population.

Material and methods

DNA samples

Blood samples were collected from 75 healthy unrelated healthy individuals and 25 Trios families (150 individuals). The Trios families included unrelated parents and at least one child. All the individuals were from the Iranian population. Genomic DNA was extracted from peripheral blood lymphocytes by standard salting out procedure (Miller et al., 1988).

Genotyping

D5S351 (UniSTS: 8886) and D5S1414 (UniSTS: 149791) markers located on the SMA critical region were genotyped. The genomic position of these two markers is represented in Fig. 1. Amplification condition for D5S1414 marker was as follows: 5 cycles consisting of primary denaturation at 94 °C for 9 min, denaturation at 94 °C for 15 s, annealing at 60 °C for 15 s, and extension at 72 °C for 30 s followed by 20 cycles consisting of denaturation at 94 °C for 15 s, annealing at 55 °C for 15 s, and extension at 72 °C for 30 s, followed by an extension period of 5 min at 72 °C. Temperature cycling conditions for D5S351 marker were as follows: primary denaturation 5 min, 94 °C; denaturation 15 s, 94 °C; annealing 15 s, 59 °C; extension 30 s, 70 °C; 23 cycles; final extension 5 min, 72 °C. Each 50 μL reaction contained 50 ng DNA, 5 μL of 500 mM KCl, 100 mM Tris–HCl (pH 8.4), 1–2 μl of 50 mM MgCl2, and 2 μL of 10 mM dNTP, 5 U SMQ-Taq DNA polymerase and 0.4 μL of 10 pM each primer.
Fig. 1

Diagrammatic representation of the location of D5S351 and D5S1414 markers at the SMA critical region. CEN, centromer; TEL, telomere; NIAP, Neural inhibitory apoptosis protein.

The amplified alleles were resolved by vertical gel electrophoresis through 10% non-denaturing polyacrylamide gel. The alleles were isolated and sequenced on an ABI 737 sequencer (Perkin Elmer/ABI, Life Technologies, Germany).

Statistical analysis

Allele frequency, observed and expected heterozygosity were calculated with GENEPOPE sofware (Raymond and Rousset, 1995). The matching probability (pM), power of discrimination (PD) and exclusion (PE), polymorphism information content (PIC) and typical paternity index (PItypical) were calculated by use of the PowerStats Microsoft Excel workbook template provided by promega cooperation (http://www.promega.com/geneticidtools/powerstats/). The genotype data obtained from 25 trios families and 75 unrelated individuals were used to estimate the haplotype frequency by use of FBAT and PHASE programs, respectively (Rabinowitz, 2000, Marchini et al., 2006). We also used 2LD program for the estimation of linkage disquilibrium (LD) between D5S351 and D5S1414 markers in the studied population (Zhao, 2004).

Results

In the present study, two STR markers including D5S351 and D5S1414 located in the SMA critical region were genotyped. The allele frequency distributions and heterozygosity of the markers were determined. Moreover, several statistical values including matching probability (pM), power of discrimination (PD) and exclusion (PE), polymorphism information content (PIC) and typical paternity index (PItypical) were determined. As presented in Table 1, a total of 15 different alleles for the markers were observed including six for D5S351 and nine for D5S1414 marker. The allele frequencies ranged from 0.007 to 0.393. The observed heterozygosity of D5S351 and D5S1414 were 51 and 52%, respectively. The highest PIC and PD was observed in D5S1414 marker (PIC: 0.82; PD: 0.940).
Table 1

Allele frequency and statistical values estimated for D5S351 and D5S1414 markers in the Iranian population.

Allele (the number of repeats)D5S351
D5S1414
Freq
120.007
130.040
140.153
150.087
160.127
170.3070.280
180.0530.073
190.3930.113
200.0270.120
210.120
220.100
Hobs51%52%
Hexp55%63%



Forensic statistics
pM0.1320.060
PIC0.680.82
PD0.8680.940



Paternity statistics
PE0.3980.418
PIT1.561.63

Hobs, observed heterozygosity; Hexp, expected heterozygosity; pM, matching probability; PIC, polymorphism information content; PD, power of discrimination; PE, power of exclusion; PIT, typical paternity index.

The haplotype frequency of haplotype D5S351–D5S1414 estimated by FBAT and PHASE programs is shown in Table 2. The haplotypes 19–17, 19–16, 17–14, 17–17, 17–18 and 19–20 were shown the frequency > 0.05, indicating these haplotypes could be introduced as informative haplotypes of D5S351–D5S1414 in the Iranian population.
Table 2

The frequency of D5S351–D5S1414 haplotypes estimated by means of FBAT and PHASE programs in the Iranian population.

D5S351–D5S1414 haplotypeFBAT frequencyPHASE frequency
19–170.1300000.141453
19–160.0850000.087432
17–140.0800000.081057
17–170.0700000.062256
17–180.0700000.057010
19–200.0500000.065244
21–140.0450000.037837
19–140.0450000.031105
17–200.0400000.034700
19–190.0350000.035859
21–170.0300000.029241
19–150.0300000.024416
22–170.0300000.054047
21–190.0300000.015131
17–130.0300000.022134
21–150.0250000.022569
17–160.0250000.011085
18–170.0200000.029670
17–190.0150000.024010
21–200.0100000.016722
18–190.0100000.013381
22–190.0100000.011619
17–120.0100000.008333
19–180.0100000.015974
18–160.0100000.008333
20–160.0100000.008333
21–160.0100000.018150
17–150.0100000.016081
18–130.0050000.004348
18–150.0050000.002600
19–130.0050000.006851
21–180.0100000.002016
22–150.0000000.001001
The D′ coefficient for haplotype D5S351–D5S1414 was estimated 0.396. The χ2 value for this haplotype obtained by means 2LD program was 82.43 (df = 40), revealing that the estimated χ2 value was higher than χ2 value obtained by using χ2 table (p < 0.05). The obtained results were supported from partially linkage between these two markers in the Iranian population.

Discussion

The purpose of the present study was to investigate the allele frequency and haplotype estimation of two short tandem repeat (STR) markers, D5S351 and D5S1414 in the Iranian population. The data indicated that two studied STRs could suggest as informative markers in linkage analysis and molecular diagnosis of SMA mutations in the Iranian population. The data showed the presence of six different alleles for the D5S351 marker in the studied population. The identified alleles were corresponded to 17, 18, 19, 20, 21 and 22 repeats of CA sequence (Table 1). Also, nine alleles were identified for D5S1414 marker including 12, 13, 14, 15, 16, 17, 18, 19, 20 repeats of the CA sequence. The most common allele for D5S351 and D5S1414 marker were 19 and 17, and the alleles with 20 and 12 CA repeats had the lowest frequency, respectively (Table 1). The heterozygosity of the D5S351 and D5S1414 markers were almost 50%, indicating these two markers were suitable in linkage analysis status in SMA families (Table 1). The discrimination power of these markers was very high. Therefore, these markers could also be used to distinguish between two unrelated people, suggesting that these markers could be applicable in forensic testing and individual identification in the Iranian population. Although, the markers have not been reported to be used in forensic testing in other populations yet, however, in view of the present data, they could be suggested to be examined as possible informative markers for other populations. Obviously, their power of discrimination needs to be tested in other populations before their application as useful markers in forensic testing. Among 54 estimated possible haplotypes for D5S351–D5S1414, thirty three haplotypes was found in the studied population. Six haplotypes, including 19–17, 19–16, 17–14, 17–17, 17–18 and 19–20, showed the frequency > 0.05 in the studied population. These haplotypes were introduced as informative haplotypes for D5S351–D5S1414 in the Iranian population. In contrast, haplotypes such as 22–17, 21–19, 17–16 and 21–18 which showed different frequency using FBAT and PHASE with at least in one program < 0.05, could not be considered as informative. The estimation of D′ coefficient and χ2 value of D5S351–D5S1414 revealed the presence of linkage disequilibrium between the two STR markers. However, these markers were not in complete linkage disequilibrium. The obtained data from D5S351–D5S1414 haplotypes study could be utilized as advantageous tools in analysis of all transmission in molecular diagnosis SMA disease. In this study, the investigation of D5S351 and D5S1414 polymorphic markers revealed that these two markers could be used as informative markers in molecular diagnosis of SMA disease in families with an affected child. Moreover, our results indicated that these markers are suitable in personal identification for legal purposes among the Iranian population.
  27 in total

1.  Parents of children with spinal muscular atrophy are not obligate carriers: carrier testing is important for reproductive decision-making.

Authors:  Susan Zeesman; Donald T Whelan; Nancy Carson; Jean McGowan-Jordan; Tracy L Stockley; Peter N Ray; Thomas W Prior
Journal:  Am J Med Genet       Date:  2002-01-22

2.  Genetic risk assessment in carrier testing for spinal muscular atrophy.

Authors:  Shuji Ogino; Debra G B Leonard; Hanna Rennert; Warren J Ewens; Robert B Wilson
Journal:  Am J Med Genet       Date:  2002-07-15

3.  A comparison of phasing algorithms for trios and unrelated individuals.

Authors:  Jonathan Marchini; David Cutler; Nick Patterson; Matthew Stephens; Eleazar Eskin; Eran Halperin; Shin Lin; Zhaohui S Qin; Heather M Munro; Goncalo R Abecasis; Peter Donnelly
Journal:  Am J Hum Genet       Date:  2006-01-26       Impact factor: 11.025

4.  Ramblings in the history of spinal muscular atrophy.

Authors:  Victor Dubowitz
Journal:  Neuromuscul Disord       Date:  2008-10-31       Impact factor: 4.296

5.  Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3.

Authors:  L M Brzustowicz; T Lehner; L H Castilla; G K Penchaszadeh; K C Wilhelmsen; R Daniels; K E Davies; M Leppert; F Ziter; D Wood
Journal:  Nature       Date:  1990-04-05       Impact factor: 49.962

6.  Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number.

Authors:  P E McAndrew; D W Parsons; L R Simard; C Rochette; P N Ray; J R Mendell; T W Prior; A H Burghes
Journal:  Am J Hum Genet       Date:  1997-06       Impact factor: 11.025

Review 7.  An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA).

Authors:  B Wirth
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

8.  The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy.

Authors:  N Roy; M S Mahadevan; M McLean; G Shutler; Z Yaraghi; R Farahani; S Baird; A Besner-Johnston; C Lefebvre; X Kang
Journal:  Cell       Date:  1995-01-13       Impact factor: 41.582

9.  Large linkage analysis in 100 families with autosomal recessive spinal muscular atrophy (SMA) and 11 CEPH families using 15 polymorphic loci in the region 5q11.2-q13.3.

Authors:  B Wirth; E Pick; A Leutner; A Dadze; B Voosen; M Knapp; B Piechaczek-Wappenschmidt; S Rudnik-Schöneborn; J Schönling; S Cox
Journal:  Genomics       Date:  1994-03-01       Impact factor: 5.736

10.  Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators.

Authors:  J Melki; P Sheth; S Abdelhak; P Burlet; M F Bachelot; M G Lathrop; J Frezal; A Munnich
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.